Quinacrine

What is Quinacrine

NOTE: This drug is discontinued in the US.

Quinacrine is an oral antiprotozoal agent used most commonly in the treatment of giardiasis. During World War II, quinacrine was effectively and widely used as an antimalarial agent. It also has been used in the treatment of cestodiasis.

More recently, quinacrine has been replaced by other agents, such as praziquantel and chloroquine, in the treatment of malaria and cestodiasis.

Cross-resistance can occur between quinacrine and chloroquine. Quinacrine was introduced as an antimalarial in 1930.

FDA approval is recorded in 1964. Production of quinacrine tablets was discontinued by the sole manufacturer in 1991, however, some pharmacies may compound quinacrine capsules from supplies of bulk powder.

Indications

  1. cestodiasis
  2. Diphyllobothrium latum
  3. Dipylidium caninum
  4. Giardia lamblia
  5. giardiasis
  6. Hymenolepis diminuta
  7. Hymenolepis nana
  8. malaria
  9. Plasmodium falciparum
  10. Plasmodium malariae
  11. Plasmodium vivax
  12. Taenia saginata
  13. Taenia solium

Side Effects

  1. abdominal pain
  2. anxiety
  3. aplastic anemia
  4. contact dermatitis
  5. diarrhea
  6. dizziness
  7. elevated hepatic enzymes
  8. euphoria
  9. exfoliative dermatitis
  10. headache
  11. hepatitis
  12. lichen planus-like eruption
  13. nail discoloration
  14. nausea
  15. nightmares
  16. pancytopenia
  17. psychosis
  18. restlessness
  19. retinopathy
  20. secondary malignancy
  21. seizures
  22. skin discoloration
  23. urine discoloration
  24. urticaria
  25. vomiting

Monitoring Parameters

  • CBC
  • ophthalmologic exam
  • stool exam

Contraindications

  • alcoholism
  • breast-feeding
  • cardiac disease
  • driving or operating machinery
  • G6PD deficiency
  • geriatric
  • hepatic disease
  • infants
  • porphyria
  • pregnancy
  • psoriasis
  • psychosis
  • renal disease
  • renal impairment

Interactions

No information is available regarding drug interactions associated with Quinacrine 

You cannot copy content of this page